We propose that a C-type lectin receptor, SIGNR-1 (also called Cd209b), helps to condition dendritic cells (DCs) in the gastrointestinal lamina propria (LPDCs) for the induction of oral tolerance in a model of food-induced anaphylaxis. Oral delivery of BSA bearing 51 molecules of mannoside (Man 51 -BSA) substantially reduced the BSA-induced anaphylactic response. Man 51 -BSA selectively targeted LPDCs that expressed SIGNR1 and induced the expression of interleukin-10 (IL-10), but not IL-6 or IL-12 p70. We found the same effects in IL-10-GFP knock-in (tiger) mice treated with Man 51 -BSA. The Man 51 -BSA-SIGNR1 axis in LPDCs, both in vitro and in vivo, promoted the generation of CD4 + type 1 regulatory T (Tr1)-like cells that expressed IL-10 and interferon- (IFN-), in a SIGNR-1-and IL-10-dependent manner, but not of CD4 + CD25 + Foxp3 + regulatory T cells. The Tr1-like cells could transfer tolerance. These results suggest that sugar-modified antigens might be used to induce oral tolerance by targeting SIGNR1 and LPDCs. nAture medicine VOLUME 16 | NUMBER 10 | OCTOBER 2010 1 1 2 9
Analyses of DCs in tissues of the gastrointestinal tract have identified several subtypes with diverse functions, depending, in part, on the nature of the subset, maturation state and the initial stimulus from the microenvironment 1 . Disturbances at different steps in homeosta sis result in a defective tolerance state and gastrointestinal hypersen sitivity, as seen in food allergy and anaphylaxis [2] [3] [4] , but the underlying mechanism of this hypersensitivity remains unclear. At present, strict avoidance of allergen sources is the only option for alleviating poten tially fatal food anaphylaxis, highlighting the need to understand the mechanism of gastrointestinal homeostasis and to develop strategies for inducing oral tolerance.
Mucosal DCs are essential for the induction of immunity and tolerance, in part because they generate regulatory cytokines and because the cytokine milieu controls the generation of functionally diverse T cells 5 . DCs with regulatory functions have been found in Peyer's patches, the lamina propria and mesenteric lymph nodes (the MLN). Whereas DCs from both Peyer's patches and the MLN are crucial for T cell priming, DCs from the lamina propria and MLN seem to be essential for the induction of oral tolerance [6] [7] [8] [9] [10] . DCs might induce oral tolerance by inducing the generation of T cells with regulatory activities, including naturally occurring CD4 + CD25 + Foxp3 + regulatory T (T reg ) cells, type 3 helper T (T H 3) cells or Tr1 cells [11] [12] [13] . This has been highlighted by the recent observation that DCs in both the MLN and the lamina propria can convert CD4 + T cells into Foxp3 + T reg cells in vitro 14, 15 and can induce IL10-producing CD4 + Tr1like cells 16 . Although mucosal DCs are known to be crucial for the induction of immunity and tolerance, the 'decisionmaking mechanism' that generates this dichotomized response remains to be fully defined.
DCs use their innate patternrecognition Tolllike receptors (TLRs) and Ctype lectin receptors (CLRs) to generate innate immunity and influence the adaptive response 17, 18 . CLRs recognize complex glycan structures on various pathogens through their Ctype carbohydrate recognition domains (CRDs) and have evolved to facilitate the endo cytosis of pathogens 19, 20 , but the exact expression profiles of various CLRs in specific subsets of DCs remain to be defined. Among the mouse homologs of the human CLR DCSIGN, it seems that SIGNR1, which has a binding specificity similar to those of human DCSIGN and its homolog LSIGN, is mainly expressed in the peritoneal macrophages and lymphoid endothelium [21] [22] [23] , although its expression level and cell type specificity remain unclear. Also, depending on their tissue localiza tion and differentiation state, DC subsets with different sets of CLRs can recognize distinct classes of infectious agents to induce tolerance or activate immunity, a process in which complex glycan structures on pathogens might have a key role 18 . The efficiency and specificity of the ligandCLR interaction may be major factors in determining the immune outcomes and could potentially be harnessed into a target ing strategy for the induction of tolerance. Here our goal was to test the hypothesis that targeting the intestinal DCs with neoglycoantigen (sugarmodified antigen), mimicking highly mannosylated struc tures on pathogens, leads to the induction of oral tolerance by CLRs in a prophylactic model of food allergy. We show that oral delivery of Man 51 BSA selectively targets LPDCs through SIGNR1 and induces the expression of IL10, leading to the induction of tolerance.
RESULTS

Sugar-modified BSA protects mice from BSA-induced anaphylaxis
To investigate whether BSA coupled with mannoside mediates a differential immune response in vivo, we used a mouse model of food allergy 24 and treated mice with BSA plus cholera toxin (a com monly used adjuvant) or mannosylated BSA with 51 molecules of mannosides (Man 51 BSA; Supplementary Fig. 1 ; refs. 25,26) plus cholera toxin. C3H/HeJ mice that were sensitized orally once each week for 7 weeks with BSA (200 μg per mouse) and cholera toxin (10 μg per mouse) showed signs of hypersensitivity after chal lenge with BSA (mean symptom severity score 4 out of 5 (fatality)); mice sensitized with Man 51 BSA (200 μg per mouse plus 10 μg per mouse of cholera toxin) did not develop any signs of hypersensitivity after challenge with BSA ( Fig. 1a) or with Man 51 BSA (data not shown). BSAsensitized mice that were pretreated with Man 51 BSA (200 μg per mouse without cholera toxin), but not with BSA, showed a significant decrease in the severity of anaphylaxis after challenge with BSA (P < 0.05; Fig. 1b) .
The reduced anaphylactic response in mice treated with Man 51 BSA was associated with significant decreases in plasma hista mine (P < 0.05; Fig. 1c ) and vascular permeability upon challenge ( Supplementary Fig. 2 ). When we measured serum levels of BSA specific antibodies, mice that had been both sensitized and chal lenged with BSA showed significant levels of IgE, IgG1 and IgG2a (P < 0.05 in all cases), whereas mice that had been pretreated with Man 51 BSA did not show any appreciable increase in IgE and IgG1 antibodies. Mice treated with Man 51 BSA showed a modest increase in IgG2a before sensitization with BSA ( Fig. 1d) , but no further increase after BSA sensitization.
Mice that received adoptive transfers of splenocytes from Man 51 BSA-treated mice showed significant decreases in anaphy lactic response (P < 0.05; Fig. 1e ) and plasma histamine concen tration (P < 0.05; Fig. 1f ) after sensitization and challenge when compared to mice that received cells from BSAtreated mice. This effect was not due to the development of naturally occur ring CD4 + CD25 + Foxp3 + T reg cells in Man 51 BSA-treated mice, as we found no significant increase in T reg cells or Foxp3 expression after sensitization with BSA in Peyer's patches, the MLN ( Supplementary Fig. 3 ) or the spleen ( Fig. 1g ) 5 d after the last oral administration of BSA or Man 51 BSA, when splenocytes can transfer tolerance.
Man 51 -BSA targeted LPDCs
To determine whether Man 51 BSA could target mucosal DCs in vivo, we treated naive mice orally with FITClabeled Man 51 BSA or BSA and carried out flow cytometry analyses of the cells isolated 6 h later from the lamina propria, Peyer's patches, MLN and spleen. We found considerable staining of DCs coexpressing CD11c and CD11b in the lamina propria, with around 50% of those cells staining positive for FITC-Man 51 BSA ( Fig. 2a) . By contrast, we found few, if any, positively stained cells in other cell subsets, includ ing CD11c − CD11b + macrophages ( Fig. 2a ) in the lamina propria and in DCs from the MLN, Peyer's patches and spleen (data not shown). Immunocytochemical analyses of the small intestine also showed that most of the cells that took up FITC-Man 51 BSA were CD11c + DCs (Fig. 2b) , as judged by marked dualcolor staining of CD11c + cells in the lamina propria of mice that received Man 51 BSA. In contrast, the lamina propria of BSAtreated mice contained no apparent costained cells. At this time point, most of the labeled BSA was localized in the epithelium with diffuse staining patterns ( Fig. 2b) . Phenotypic analysis of this CD11c + CD11b + LPDC subset revealed that it expressed the major histocompatibility complex class II molecule IA, CD80, CD40, the chemokine receptor CCR7 and the αintegrin CD103, whereas it did not express CD8α, the B cell-associated marker B220, CD45RB or the macrophage marker F4/80 ( Supplementary Fig. 4 ). 
Expression of SIGNR1 in mucosal DCs
To determine which CLR is responsible for taking up Man 51 BSA, we carried out flow cytometry analyses of intestinal DCs to pro file the expression patterns of selected CLRs, including SIGNR1 and mannose receptor (CD206), both of which bind mannosebearing antigens. Analyses of LPDCs showed that SIGNR1 was expressed selectively in the CD11c + CD11b + DC subset ( Fig. 2c) , whereas DCs from spleen showed no expression of SIGNR1, as confirmed by quantitative PCR analyses ( Fig. 2d) . These analyses showed that CD205 was selectively expressed in the CD11c + CD11b − DC subset, whereas dectin1, the yeast zymosan receptor, seemed to be mainly expressed in the CD11c + CD11b + subset, and DCs showed variable expression of CD206 and dectin2 ( Supplementary Fig. 5 ).
To test whether Man 51 BSA is a ligand for SIGNR1, we analyzed the ability of Man 51 BSA and other sugarmodified BSA derivatives, including galactosylated BSA (Gal 34 BSA), to bind SIGNR1. Mouse SIGNR1 showed considerable binding to Man 51 BSA but negligible binding to BSA and Gal 34 BSA (Fig. 3a) . To confirm its binding, we performed a cellbased, competition analysis of SIGNR1transfected cells, using FITClabeled dextran, a known ligand for SIGNR1 23 , and varying concentrations of neoglycoantigens as competitors. Man 51 BSA inhibited, in a dosedependent manner, the labeled dextran's binding to SIGNR1 but did not compete significantly with BSA (not shown), Gal 34 BSA or a mannosylated BSA derivative, Man 8 BSA, that has a much lower density of mannosides ( Fig. 3b) .
Man 51 -BSA selectively induces IL-10 expression in LPDCs
To investigate the functional effect of the Man 51 BSA-SIGNR1 axis, we examined the concentrations of cytokines in CD11c + DCs from the lamina propria stimulated with BSA or Man 51 BSA. As expected, CpG, a TLR9 agonist, induced the expression of IL10, IL12 and IL6 in all DC subsets ( Fig. 3c,d) . In CD11c + LPDCs, Man 51 BSA significantly induced the expression of IL10 (P < 0.05; Fig. 3c ), but not of IL6, IL12 p70 ( Fig. 3d) , IL27 or transforming growth factor β (TGFβ) (data not shown); in contrast, CD11c − CD11b + cells from the lamina propria ( Fig. 3e) and CD11c + spleen DCs (Fig. 3f ) showed no detectable IL10 expression after stimulation with Man 51 BSA.
The addition of a SIGNR1specific blocking antibody or of mannan (a weak SIGNR1 antagonist) significantly decreased IL10 in Man 51 BSAtreated LPDCs (P < 0.05; Fig. 4a ). Moreover, the presence of a CD206 specific blocking antibody did not inhibit IL10 expression induced by Man 51 BSA (Fig. 4b) , nor did the addition of an inhibitor for MyD88, a TLR signaling molecule, as compared to that seen in medium control or in cultures with an irrelevant peptide ( Fig. 4c) . In contrast, the induction of IL10 in LPDCs by CpG was significantly inhibited in the presence of a MyD88 peptide inhibitor ( Fig. 4c) . Furthermore, IL10 expression in LPDCs induced by Man 51 BSA was associated with the activation of a member of the mitogenactivated protein kinase family, cJun Nterminal kinase, but not of p38 or extracellular signal-regulated kinase (Supplementary Fig. 6) , consistent with those noted in a mouse RAW cell line overexpressing SIGNR1Flag fusion proteins and activated with a Flagspecific antibody 27 . Moreover, analysis of intestinal DCs from IL10-GFP tiger mice 28 corroborated the finding that LPDCs are the primary targets of Man 51 BSA, as the percentage of GFP + CD11c + DCs increased from 1.7% to 7.3% in the lamina propria of mice that had received Man 51 BSA (Fig. 4d) , whereas the spleen contained far fewer GFP + cells (0.5%) and there was no difference in the number of GFP + cells from the MLN and Peyer's patches at this time point (data not shown).
Man 51 -BSA-treated DCs promote the generation of Tr1-like T cells Next we investigated effects of Man 51 BSA-treated LPDCs on the T cell differentiation pathway. We found significantly increased con centrations of IL10 and IFNγ in T cells cultured with Man 51 BSApulsed LPDCs (P < 0.05; Fig. 5 ) as compared to BSApulsed cells. This effect was ablated by a SIGNR1blocking antibody ( Fig. 5a) or an IL10-neutralizing antibody (Fig. 5b) , but not by a TGFβ-neutra lizing antibody (data not shown). The frequency of Foxp3 + T cells in the cocultures remained similar throughout the assay period (data not shown). When we used CpG as an additional stimulus, we found no significant difference in the amount of cytokines in T cells cocultured with either BSA or Man 51 BSA-pulsed DCs (data not shown).
We noted a similar pattern of T cell differentiation into IL10-and IFNγ-expressing cells in vivo in CD4 + T cells from mice treated with Man 51 BSA, but not BSA, after stimulation (Fig. 5c) . Mice that received adoptive transfers of CD4 + T cells, but not of CD11c + splenic DCs, from mice treated with Man 51 BSA, but not with BSA, showed decreases in anaphylactic response (P < 0.05; Fig. 5d ) and plasma histamine concentration (P < 0.05; Fig. 5e ).
SIGNR1 and IL-10 are necessary for tolerance induction
To determine whether SIGNR1 is required for the induction of tolerance by Man 51 BSA, we analyzed the generation of splenic Tr1like T cells in vivo in SIGNR1deficient and wildtype mice (C57BL/6 background). Man 51 BSA did not induce expression of IL10 ( Fig. 6a) and IFNγ (Fig. 6b) in Tr1like T cells from SIGNR1deficient mice treated with Man 51 BSA when compared with wildtype mice treated with Man 51 BSA. Moreover, although C57BL/6 mice are known to be a poor IgE and T H 2 responder strain, and the severity of anaphylaxis in these mice (a) Cells were stimulated with medium alone, BSA (20 μg ml −1 ) or Man 51 -BSA (20 μg ml −1 ) with or without a blocking SIGNR1-specific antibody (50 μg ml −1 ), isotype control (Ig Ctr) or, in separate assays, mannan (20 μg ml −1 ). (b) Cells were stimulated as in a with or without an antibody specific to mannose receptor (CD206; 50 μg ml −1 ) or isotype control. tends to be milder than that seen in the C3H/HeJ strain, we found significantly more severe symptoms (P < 0.05; Fig. 6c ) and plasma histamine concentrations (P < 0.05; Fig. 6d ) in SIGNR1deficient mice treated with Man 51 BSA compared with wildtype mice treated with Man 51 BSA after sensitization and challenge with antigen. Man 51 BSA-mediated suppression of antigeninduced anaphylactic severity ( Fig. 6e) and plasma histamine abundance (Fig. 6f) was no longer apparent when C3H/HeJ mice received IL10 receptor (IL10R) specific, but not isotype control, antibodies 1 day before and 2 weeks after the initial antigen sensitization. The inability of Man 51 BSA to induce tolerance was also seen in mice receiving a transfer of splenic CD4 + T cells from Man 51 BSA-treated, IL10-deficient, mice, but not from wildtype mice, as we found no significant reduction in symptom scores (Fig. 6g) or specific IgG1 concentrations (Fig. 6h) . Also, Man 51 BSA-mediated tolerance to the antigeninduced IgG1 response was lost in IL10-deficient mice as compared with that of wildtype mice (data not shown). These results suggest, therefore, the crucial role of IL10 from Man 51 BSA-modified LPDCs in generating Tr1like T cells and in conferring the suppressive activity of Tr1like T cells on the antigeninduced anaphylactic response.
DISCUSSION
We have provided evidence that a sugarmodified antigen, Man 51 BSA, can induce oral tolerance in a model of food allergy by a sequen tial process originating from targeting of LPDCs by Man 51 BSA and leading to the development of CD4 + , Tr1like T cells that express IL10 and IFNγ in the spleen. SIGNR1 and IL10 seem to be crucial for this process. Although the expression of CCR7 and CD103 in the CD11c + CD11b + LPDC subset seemed indistinguishable from that in the CD11c + CD11b − DC subset, the pattern of CLR expres sion varied between subsets. SIGNR1 expression seemed to mark the CD11c + CD11b + CD8 − subset and served as the primary CLR in medi ating the effect of Man 51 BSA. Functionally, the Man 51 BSA-SIGNR1 axis generated tolerogenic DCs by inducing the expression of IL10, and Man 51 BSA-mediated tolerance required SIGNR1 and IL10.
The finding that spleen DCs from mice treated with Man 51 BSA could not transfer tolerance is consistent with their inability to respond to Man 51 BSA in vitro. This might be due to their lack of, or low level of, SIGNR1 expression, and also to the possibility that they are resident in the spleen and are not migratory. Our results suggest that the mucosal immune response, particularly in the villous lamina propria, which accounts for most protein uptake from the intestine 9 , can be preprogrammed for the induction of tolerance through the CLRligand interaction. It is unclear where Tr1like T cells were primed by Man 51 BSA-stimulated DCs. The Man 51 BSA-targeted CD11c + CD11b + LPDC subset expressed CCR7, suggesting that they might migrate into the MLN with subsequent priming of Tr1like T cells. This possibility is supported by the finding that CCR7 dependent migration of DCs from the lamina propria to the MLN is required for the induction of oral tolerance 29 . A detailed kinetic analysis is required to track the migratory patterns of DCs and the development of Tr1like T cells in situ.
Spleenderived DCs that have a plasmacytoid phenotype (CD45RB + B220 + ) can be modified by TGFβ-induced T reg cells, with subsequent generation of IL27, which promotes the develop ment of IL10-expressing Tr1 cells 30 . By contrast, Man 51 BSAtargeted CD11c + CD11b + LPDCs did not express CD45RB and B220, could not secrete IL27 and TGFβ after activation with Man 51 BSA and had no effect on the generation of T reg cells. These phenotypic and functional features distinguish LPDCs from spleenderived, CD45RB + B220 + plasmacytoidlike DCs and from mucosal DCs that can induce T reg cells through TGFβ 14 . Although Man 51 BSA could elicit IL10 production in LPDCs with subsequent generation of Tr1like T cells in the absence of TLR signaling, its selective effect on IL10 expression in T cells was lost when a TLR9 agonist, CpG, was added to the culture. Therefore, it is likely that the nature of the ligandreceptor axis in DC priming can determine the DCs' function. The selective expression of SIGNR1 and its candidacy as a target for induction of IL10 in LPDCs might therefore represent a previously undescribed role of tolerogenic DCs in the intestinal mucosa in main taining the homeostatic state.
There has been an intense interest in determining how DCs are programmed to generate immunity or induce tolerance, and the DCexpressed CLRs, with their diverse roles in antigen uptake and interactions between T cells and DCs, have been considered attractive targets. For example, injection of yeast zymosan plus ovalbumin in mice induces T cell tolerance through TLR2 and the CLR dectin1 (ref. 31) . Also, targeting of DEC205 by a specific antibody has been shown to generate T cell tolerance 32 . A similar tolerogenic activity has also been found for human DCSIGN 33 . Furthermore, DCs can be rendered tolerogenic when exposed to galectin1, a glycanbinding protein, and this promotes IL27-dependent and IL10-mediated T cell tolerance 34 . These studies, combined with the finding that DCspecific immune receptor, a member of the CLR family, is a nega tive regulator of DC expansion 35 , support the role of the CLRligand axis in immune modulation. There is evidence that pro and prebiotics might be useful for alleviating allergic responses 36 , but in most studies the detailed mecha nisms are unclear, and the potential development of anaphylaxis upon delivery remains a major concern. Engineering, with relatively simple synthetic chemistry, sugarmodified antigens to target tolerogenic DCs could circumvent these limitations and offer safer and more efficacious designs. Notably, feeding a prebiotic formula with oligosaccharides to infants with a parental history of atopy has been associated with a lower incidence of allergic diseases 37 . The potential modulatory effect of oligosaccharides and, perhaps, microbials 38 might be mediated through the ligandCLR axis, providing a conditioning effect on mucosal DCs. The integration by DCs of CLR signaling to control innate immunity and adaptive responses might thus represent a key mechanism for controlling mucosal immunity and could help in the design of effective strategies for alleviating the increasingly common and potentially fatal problem of food allergies.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METhODS
Mice, sensitization and challenge. Four to sixweekold male and female mice (C3H/Hej, C57BL/6, IL10deficient (B6.129P2IL10 tm1Cgn /J), IL10-GFP knockin (tiger) from the Jackson Laboratory and SIGNR1deficient mice from the Consortium for Functional Glycomics) were maintained under specific path ogen-free conditions, and all experiments were approved by the Animal Care and Use Committee at Johns Hopkins University School of Medicine. Mice received seven weekly sensitizations with PBS or BSA (SigmaAldrich) (200 μg per mouse) plus cholera toxin (B subunit: 10 μg per mouse (List Biological Laboratories)) as adjuvant, and 1 week after the final sensitization they were challenged intraperi toneally with 1 mg of BSA. In some cases, C3H/HeJ mice were injected intra peritoneally with antibody to IL10R receptor (0.25 mg per mouse; clone 1B1.3a, BD Biosciences) 1 d before and 2 weeks after the initial sensitization.
Coupling of BSA with mannosides or galactosides was performed as previ ously described 25, 26 . Mice were orally treated with 200 μg per mouse of BSA or Man 51 BSA for three successive days before the first sensitization. Systemic anaphylaxislike symptoms were evaluated in a blinded manner within 30 min after challenge using a previously described scoring system 24 . Plasma histamine concentrations were determined by enzyme immunoassays, and serum antibody concentrations were analyzed by ELISA 24 before and after sensitization.
Binding analysis and analyses of immunological responses.
The binding activity of neoglycoantigens to SIGNR1 was determined by solidphase binding assays as previously described 39 . A cellbased competition analysis of SIGNR1 transfectant BaF3 cells was performed with varying concentrations of neoglyco antigens as competitors in the presence of FITClabeled dextran (2,000 kd, 10 μg ml −1 (SigmaAldrich)), a known ligand for SIGNR1 (ref. 23) .
Singlecell suspensions of intestinal lamina propria and Peyer's patches were enriched for CD11c + cells with antiCD11c MACS beads, and CD11c − CD11b + cells were positively selected from the flowthrough cells. For flow cytometric analysis of the cell target of Man 51 BSA, cells were isolated from mice 6 h after oral administration of 200 μg of Man 51 BSA or BSA labeled with FITC and stained with biotinylated FITCspecific antibody and FITCconjugated strepta vidin. For analysis of SIGNR1 expression, the cells were stained with Alexa fluor 488-conjugated antibody to SIGNR1 or isotype control and gated on the expression of CD11c (N418) and CD11b (M1/70). The relative levels of Signr1 transcripts were evaluated by quantitative RTPCR.
For analysis of Man 51 BSA target cells, frozen sections of small intestines of mice that had received FITCconjugated BSA or Man 51 BSA were incu bated with CD11cspecific antibody (hamster IgG, clone N418), Texas redconjugated hamsterspecific IgG, rabbit antibody to FITC, isotype control antibody and FITCconjugated antibody to rabbit IgG. Total lamina propria cells were isolated from IL10-GFP tiger mice on day 4 after oral administration of BSA or Man 51 BSA, and the percentage of GFP + cells was determined by gating on the CD11c + cells. For analysis of Man 51 BSA-induced cytokine production, CD11c + and CD11c − CD11b + cells (2 × 10 5 per condition) were stimulated with medium alone, BSA (20 μg ml −1 ), Man 51 BSA (20 μg ml −1 ) or 1 μM of CpG (ODN1668) in the presence or absence of antibody to SIGNR1 (50 μg ml −1 ; ERTR9), isotype control antibody, mannan (20 μg ml −1 ), antibody to mannose receptor (50 μg ml −1 ), 200 μM of a MyD88 peptide inhibitor or a control peptide, for 24 h, and cytokine levels were analyzed with ELISA. All antibody sources are in the Supplementary Methods.
For adoptive cell transfer experiments, total spleen cells, CD4 + cells or CD11c + cells positively selected from pooled spleen cells of the same group were isolated from mice 5 d after three daily oral administrations of 200 μg of BSA or Man 51 BSA and were transferred into naive mice via the tail vein 1 d before the first sensitization, followed by sensitization once a week for 7 weeks and the challenge as described above. In all cases, the purity of isolated cells was >95%, as assessed by flow cytometry. The numbers of transferred cells were 1 × 10 7 for whole spleen cells, 2 × 10 6 for isolated CD4 + cells and 1 × 10 6 for isolated CD11c + cells.
For analysis of T cell cytokines, splenic CD4 + CD62L + T cells (1 × 10 6 per condition) from naive mice were cocultured with CD11c + LPDCs (1 × 10 5 per condition) pulsed with BSA (20 μg ml −1 ) or Man 51 BSA (20 μg ml −1 ) in the pres ence or absence of antibody to SIGNR1 (50 μg ml −1 ; ERTR9) or neutralizing antibodies to IL10 (5 μg ml −1 ; JES516E3) for 96 h, followed by stimulation with or without a combination of antibodies to CD3 and CD28 (1 μg ml −1 each; 1452C11 and 37.51, respectively) for 24 h, and the abundance of cytokines were measured by ELISA. All antibody sources are in the Supplementary Methods. In some cases, splenic CD4 + T cells were isolated (1 × 10 6 cells per condition) from mice on day 8 after oral administration of PBS, BSA or Man 51 BSA (200 μg per mouse) and stimulated with antibodies to CD3 and CD28 as described above for 24 h. Further details can be found in the Supplementary Methods. Statistical analysis. Data are expressed as the means ± s.e.m. for each group. Differences in each of the quantitative parameters were analyzed by t test, and the Wilcoxon signedrank test was used to analyze differences in the anaphy lactic symptom scores. Differences among groups of mice were determined by analysis of variance (StatView). If differences between groups were significant (P < 0.05), Fisher's protected least significant difference test was used to distin guish between pairs of groups. 
